C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan

Since June 2019, under the umbrella of the national health insurance system, Japan has started cancer genomic medicine (CGM) with comprehensive genomic profiling (CGP) tests. The Ministry of Health, Labour and Welfare (MHLW) of Japan constructed a network of CGM hospitals (a total of 233 institutes...

Full description

Saved in:
Bibliographic Details
Published in:Cancer discovery 2022-11, Vol.12 (11), p.2509-2515
Main Authors: Kohno, Takashi, Kato, Mamoru, Kohsaka, Shinji, Sudo, Tomohisa, Tamai, Ikuo, Shiraishi, Yuichi, Okuma, Yusuke, Ogasawara, Daisuke, Suzuki, Tatsuya, Yoshida, Teruhiko, Mano, Hiroyuki
Format: Article
Language:English
Subjects:
Genomic Medicine
Genomics
Humans
Japan
Neoplasms - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since June 2019, under the umbrella of the national health insurance system, Japan has started cancer genomic medicine (CGM) with comprehensive genomic profiling (CGP) tests. The Ministry of Health, Labour and Welfare (MHLW) of Japan constructed a network of CGM hospitals (a total of 233 institutes as of July 1, 2022) and established the Center for Cancer Genomics and Advanced Therapeutics (C-CAT), the national datacenter for CGM. Clinical information and genomic data from the CGP tests are securely transferred to C-CAT, which then generates "C-CAT Findings" reports containing information of clinical annotation and matched clinical trials based on the CGP data. As of June 30, 2022, a total of 36,340 datapoints of clinical/genomic information are aggregated in C-CAT, and the number is expected to increase swiftly. The data are now open for sharing with not only the CGM hospitals but also other academic institutions and industries.
ISSN:2159-8274
2159-8290
DOI:10.1158/2159-8290.CD-22-0417